Shire plc SHPGY presented new data for Replagal (agalsidase alfa) in patients with Fabry disease, and VPRIV (velaglucerase alfa for injection) in patients with type 1 Gaucher disease, at the 2011 American College of Medical Genetics' (ACMG) Annual Clinical Genetics Meeting, held in Vancouver, BC, from March 16-20, 2011.
Data from clinical programs evaluating the safety of switching from Fabrazyme (agalsidase beta) to Replagal and long-term safety and efficacy of switching from Cerezyme (imiglucerase) to VPRIV were presented.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in